Natera's Q1 2017 Revenues Drop 24 Percent

May 09, 2017

|

NEW YORK (GenomeWeb) – Natera reported after the market on Tuesday that its first quarter 2017 revenues declined 24 percent over the first quarter 2016.

The San Carlos, California-based molecular diagnostics firm recognized $46.9 million in Q1 revenues, down from $61.9 million in Q1 2016. It beat analysts' average estimate of $42.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

High-Throughput Detection of SARS-CoV-2 Using COVIDSeq NGS: A GenomeWeb eCase Study Transcript

NGS-Based Target Capture for SARS-CoV-2 Detection and Characterization

Feb

22

Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb

23

Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before.

Feb

24

Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.

Menu

Natera's Q1 2017 Revenues Drop 24 Percent

To read the full story....

Breaking News

Rhinostics Licenses Procter & Gamble Nasal Swab for COVID-19 Testing

FIND, Unitaid Ink First Agreement to Enable COVID-19 Antigen Tests at $2.50 Apiece

Oppenheimer Initiates Coverage of DermTech With Outperform Rating

Invitae Prices $400M Common Stock Offering

Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

In Brief This Week: Myriad Genetics, Precipio, LumiraDx, Guardant Health, and More

Featured White Papers

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

What's Popular?

Molzym, Fraunhofer Developing Rapid Direct-From-Sample Sepsis Diagnostic Platform and Test

Devyser Receives €750K Grant to Build Sequencing Assay for Early Detection of Transplant Rejection

Sponsorships